Rep. Gilbert Ray Cisneros, Jr. Sells Off Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Representative Gilbert Ray Cisneros, Jr. (D-California) recently sold shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT). In a filing disclosed on May 06th, the Representative disclosed that they had sold between $1,001 and $15,000 in Sarepta Therapeutics stock on April 14th. The trade occurred in the Representative's "150 MAIN STREET TRUST > BANK OF AMERICA" account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $1,001 - $15,000 in shares of Beiersdorf Aktiengesellschaft OTCMKTS: BDRFF on 5/2/2025.
• Purchased $1,001 - $15,000 in shares of Alkami Technology NASDAQ: ALKT on 4/30/2025.
• Purchased $1,001 - $15,000 in shares of Merck & Co., Inc. NYSE: MRK on 4/29/2025.
• Sold $1,001 - $15,000 in shares of DXC Technology NYSE: DXC on 4/29/2025.
• Sold $1,001 - $15,000 in shares of DOW NYSE: DOW on 4/29/2025.
• Sold $1,001 - $15,000 in shares of Zions Bancorporation, National Association NASDAQ: ZION on 4/29/2025.
• Purchased $1,001 - $15,000 in shares of O'Reilly Automotive NASDAQ: ORLY on 4/29/2025.
• Purchased $1,001 - $15,000 in shares of McKesson NYSE: MCK on 4/29/2025.
• Sold $1,001 - $15,000 in shares of Amazon.com NASDAQ: AMZN on 4/29/2025.
• Sold $1,001 - $15,000 in shares of Humana NYSE: HUM on 4/29/2025.

Sarepta Therapeutics Trading Down 21.5 %

Shares of SRPT opened at $36.72 on Thursday. Sarepta Therapeutics, Inc. has a fifty-two week low of $36.59 and a fifty-two week high of $173.25. The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.03 and a current ratio of 3.84. The company's fifty day moving average is $69.47 and its 200 day moving average is $102.12. The stock has a market capitalization of $3.61 billion, a PE ratio of 29.38 and a beta of 0.85.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last released its earnings results on Tuesday, May 6th. The biotechnology company reported ($3.42) earnings per share (EPS) for the quarter, missing the consensus estimate of $2.20 by ($5.62). The firm had revenue of $744.86 million during the quarter, compared to the consensus estimate of $685.75 million. Sarepta Therapeutics had a return on equity of 11.00% and a net margin of 7.43%. Sarepta Therapeutics's revenue was up 80.2% compared to the same quarter last year. During the same quarter last year, the business posted $0.73 EPS. Sell-side analysts expect that Sarepta Therapeutics, Inc. will post 2.67 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

SRPT has been the subject of a number of recent analyst reports. Morgan Stanley dropped their price objective on Sarepta Therapeutics from $182.00 to $113.00 and set an "overweight" rating for the company in a report on Wednesday. Wells Fargo & Company initiated coverage on shares of Sarepta Therapeutics in a research note on Friday, April 11th. They set an "overweight" rating and a $115.00 target price for the company. Guggenheim reduced their price target on shares of Sarepta Therapeutics from $112.00 to $98.00 and set a "buy" rating on the stock in a research note on Wednesday. The Goldman Sachs Group lowered their price objective on shares of Sarepta Therapeutics from $178.00 to $100.00 and set a "buy" rating for the company in a research report on Wednesday. Finally, Cantor Fitzgerald reduced their target price on shares of Sarepta Therapeutics from $163.00 to $81.00 and set an "overweight" rating on the stock in a research report on Wednesday. Six investment analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $137.09.

Institutional Investors Weigh In On Sarepta Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Manchester Capital Management LLC increased its holdings in shares of Sarepta Therapeutics by 86.6% during the fourth quarter. Manchester Capital Management LLC now owns 237 shares of the biotechnology company's stock valued at $29,000 after acquiring an additional 110 shares in the last quarter. MassMutual Private Wealth & Trust FSB raised its holdings in shares of Sarepta Therapeutics by 169.6% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 248 shares of the biotechnology company's stock worth $30,000 after buying an additional 156 shares during the last quarter. Byrne Asset Management LLC acquired a new stake in shares of Sarepta Therapeutics during the first quarter worth $30,000. Center for Financial Planning Inc. purchased a new stake in shares of Sarepta Therapeutics during the first quarter valued at $31,000. Finally, Newbridge Financial Services Group Inc. acquired a new position in shares of Sarepta Therapeutics in the 4th quarter valued at $36,000. 86.68% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Sarepta Therapeutics news, Director Claude Nicaise sold 2,491 shares of Sarepta Therapeutics stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $99.64, for a total transaction of $248,203.24. Following the completion of the sale, the director now directly owns 27,812 shares in the company, valued at approximately $2,771,187.68. The trade was a 8.22 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 7.70% of the stock is currently owned by insiders.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California's 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California's 31st Congressional District. He declared candidacy for the 2026 election. Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor's degree in political science from George Washington University in 1994, a master's in business administration from Regis University in 2002, and a master's degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.